Clinical outcomes of modified transarterial chemoembolization vs. drug-eluting bead transarterial chemoembolization as initial treatment for single hepatocellular carcinoma: a propensity score matching analysis Authors: Boyang Chang, Churen Zhou, Chengcheng Liu, Luwen Mu, Mingsheng Huang, Mingjun Bai Published: 2024 ABSTRACT AbstractBackground & aimsOptimizing transarterial chemoembolization (TACE) can enhance treatment efficacy for hepatocellular carcinoma (HCC). This study compares modified TACE (M-TACE), which combines a lipiodol-based emulsion and drug-eluting beads, with drug-eluting bead TACE (DEB-TACE) as initial therapies for solitary HCC.MethodsIn this retrospective study, 185 patients undergoing M-TACE or DEB-TACE were evaluated. Propensity score matching was used to create 69 balanced pairs. Initial tumor response, repeated treatments within six months, local tumor progression (LTP), overall survival (OS), and adverse events (AEs) were assessed.ResultsM-TACE exhibited significantly higher initial complete response (CR) rates (39.1% vs. 23.2%, p = 0.043) and fewer repeated treatments within six months (1.7 ± 0.9 vs. 2.1 ± 0.7; p = 0.033) compared to DEB-TACE. LTP rates were notably lower with M-TACE at 12 months (39.1% vs. 65.2%, p = 0.002), and median time to LTP was prolonged with M-TACE (13.3 vs. 8.2 months, p = 0.038). Stratified analysis revealed a significantly longer OS in individuals achieving a CR after the initial M-TACE (50.5 vs. 33.4 months, p = 0.043). However, the overall study population did not exhibit a significant difference in OS between the two groups. Comparable AEs (all p > 0.05) were observed.ConclusionsM-TACE showed higher initial CR rates, lower LTP rates, and extended time to LTP compared to DEB-TACE, indicating its potential to enhance TACE effectiveness for solitary HCC.Keywords: Carcinoma, hepatocellular, treatment outcome, chemoembolization, therapeutic Introduction Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer-related mortality worldwide [1]. The Barcelona Clinic Liver Cancer (BCLC) staging system classifies single HCC as very early-stage (BCLC 0, less than 2 cm) or early-stage (BCLC A, one nodule). Recommended curative treatments for these stages include liver resection, transplantation, and ablation [2]. However, these options are not always feasible due to factors such as tumor location, compromised liver function, patient reluctance towards invasive procedures, or lack of donor organs [3,4]. Under such circumstances, transarterial chemoembolization (TACE) has emerged as a ­viable therapeutic alternative [5–7]. Currently, TACE can be performed using either drug-eluting bead TACE (DEB-TACE) or conventional TACE (cTACE) with lipiodol [8]. Although both methods yield comparable clinical outcomes, DEB-TACE has demonstrated a superior safety profile compared to cTACE [9–11]. DEB-TACE has gradually replaced cTACE in our center since 2015, primarily due to its better safety profile and coverage by national health insurance. The European Association for the Study of the Liver (EASL) guidelines indicate that the objective response measured by the modified Response Evaluation Criteria in Solid Tumors (RECIST) predicts overall survival (OS) in patients undergoing locoregional therapies [5]. It also highlights that patients who achieve CR following initial TACE show significantly longer OS, emphasizing the critical nature of achieving CR early in treatment [5,12,13]. Ikeda et al. demonstrated that DEB-TACE treatment achieved an initial CR rate of 35.7% in HCC ≤ 5 cm [14]. However, residual viable areas are often observed at the tumor margins after DEB-TACE, potentially reducing CR rates [15,16]. This issue may stem from the size of the drug-eluting beads, which can prevent their penetration into smaller vessels and limit their effectiveness at the tumor’s portal venous supply. In contrast, lipiodol-based emulsions can penetrate complex arterial networks, infiltrate the tumor capsule, and accumulate in the peritumoral portal vein, potentially overcoming the limitations of DEB-TACE [17,18]. Consequently, optimizing TACE techniques by combining the benefits of both embolization materials could enhance therapeutic outcomes. This study introduces a novel modified TACE (M-TACE), which combines the lipiodol-based emulsion’s infiltrative capabilities with the controlled drug release of DEBs. The primary aim of this study was to compare the clinical outcomes, including tumor response, local tumor progression (LTP), overall survival, and adverse events, between M-TACE and DEB-TACE in patients with a single HCC. Methods Study design and patients This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Sun Yat-sen University’s Third Affiliated Hospital authorized this investigation (No. II2023-020-01). Because of the retroactive nature of the research, informed consent was not mandatory. The HCC diagnosis was made based on the radiological standards outlined by the EASL and the American Association for the Study of Liver Diseases [5,6]. This retrospective comparative study comprised subjects who underwent M-TACE or DEB-TACE as initial treatment for solitary HCC at the Third Affiliated Hospital of Sun Yat-sen University from January 2016 to December 2019. Exclusion criteria encompassed: 1) tumor diameter < 3 cm; 2) tumor with extrahepatic metastasis or macrovascular invasion; 3) Eastern Cooperative Oncology Group performance status (ECOG PS) score ≥ 2; 4) Child-Pugh Class C; 5) subsequent interventions like ablation, resection or liver transplantation within 1 months after TACE; or 6) lost to follow-up. A total of 185 individuals were eligible for this study, 73 received M-TACE, and 112 received DEB-TACE. Treatments TACE was performed under local anesthesia. The procedure entailed access to the femoral artery using a catheter of 5-F RH; the tumor-feeding arteries were effectively catheterized utilizing a 2.7-F microcatheter. For DEB-TACE, CalliSpheres microspheres (Hengrui Medicine Co. Ltd., Jiangsu, China), sized 100-300 μm, were filled with 40 mg of doxorubicin per vial. These microspheres, combined with a nonionic contrast medium, were intra-arterially administered with a maximum of two vials. If necessary, additional embolization was executed using Embosphere (300-500um, Merit Medical, South Jordan, USA) and gel foam (350-550um, Cook Inc., Indiana, USA). When the contrast agent flow stagnated, embolization was stopped. For M-TACE, an emulsion of 7.5 mL was prepared by mixing doxorubicin (20 mg) with lipiodol in a 1:2 ratio. Under radiographic guidance, the emulsion was delivered into the targeted tumor until the entire tumor outline became discernible. Typically, the emulsion volume depended on the tumor diameter: less than 2.5 mL for tumors varying from 3-5 cm, less than 5 mL for tumors size from 5-10 cm, and fewer than 7.5 mL for tumors greater than 10 cm. Subsequently, CalliSpheres microspheres loaded with 40 mg of doxorubicin were administered as described above, followed by embolization with Embosphere or gel foam if necessary. All patients in the study were treated with TACE by the same medical team. The choice of TACE treatment was made jointly by the medical team and the patients, with their signatures confirming the decision. Outcomes The initial tumor response rate, LTP rate, duration to LTP, the number of repeated treatments within six months, OS, and adverse events (AEs) were observed. Tumor response at four to six weeks after the initial cycle of TACE was assessed using MRI or dynamic CT. The assessment categorized cancer response into CR, stable disease (SD), partial response (PR), or progressive disease (PD) depending on the mRECIST [19]. The objective response rate (ORR) was determined by estimating the ratio of cases that achieved CR or PR. The time to LTP was defined as the duration between the date of DEB-TACE or M-TACE and the initial occurrence of local tumor progression observed in CT/MRI images for the treated HCC. OS was determined as the duration from the primary TACE therapy and mortality from any reason. Adverse events (AEs) were evaluated depending on version 5.0 of Common Terminology Criteria for Adverse Events [20]. Follow-up All enrolled patients underwent regular follow-up assessments at our institution, with the first evaluation occurring at 4-6 weeks post-initial TACE and subsequent assessments scheduled every three months until the identification of tumor recurrence. These follow-up sessions encompassed comprehensive clinical examinations, laboratory analyses, and abdominal contrast-enhanced CT or MRI scans. In cases where patients exhibited residual viable tumors or experienced tumor recurrences in dynamic CT or MRI examinations, and their clinical status permitted, a repeated TACE procedure was undertaken. The approach for the second TACE intervention depended on the extent and spread of the residual or recurrent viable tumors, as well as the patient’s clinical condition and the operator’s expertise. Notably, if patients manifested vascular invasion or extrahepatic metastasis, they would combine systemic therapy. The last follow-up was on November 30, 2022. Statistical analyses We used a quasi-experimental design with one-to-one propensity score matching (PSM) to mimic a randomized clinical trial to decrease patient prejudice and equalize factors between the two categories. The selected factors in the propensity model were age, sex, hepatitis status, Child-Pugh class, ECOG PS score, tumor diameter, alpha-fetoprotein (AFP), total bilirubin and albumin. The nearest neighbor matching approach was used with a caliper of 0.2. The method functionally relied on the R package MatchIt. In the final analysis, 69 pairs of patients were included. All data were studied employing R software, version 4.2.2, SPSS 23.0 and GraphPad Prism 8.0. Standardized mean difference (SMD) was used to examine the balance of covariate distribution between groups. Data were analyzed using descriptive statistics (mean and standard deviation, sd) and compared with chi-square or Fisher exact test for categorical data and Student’s t-test for continuous variables. Time to LTP and OS were analyzed employing the Kaplan-Meier method, and the log-rank test was utilized to compare them. The variables with a statistical significance of p < 0.1 in the univariable analysis entered the multivariable Cox regression analysis. The statistical tests conducted were two-sided, and a P value <0.05 was deemed to be statistically significant. Results Baseline characteristics A total of 138 patients were included in the study, with 69 in each group after PSM (Figure 1). The results of PSM show the baseline equilibrium between M-TACE group and DEB-TACE group (Table 1). After receiving the first TACE treatment, the patient’s subsequent treatment details are shown in Table S1. Flow chart. Table 1.Baseline characteristics of patients before and after PSM.Variables Before MatchingAfter MatchingDEB-TACE(n = 112)M-TACE(n = 73)PValueSMDDEB-TACE(n = 69)M-TACE(n = 69)PValueSMDAge, yearsMean (SD)55.53 (11.31)54.66 (12.61)0.633−0.06955.03 (11.21)54.84 (12.80)0.927−0.015Sex (%)Male97 (86.6)62 (84.9)0.749−0.04760 (87.0)59 (85.5)0.805−0.041 Female15 (13.4)11 (15.1) 0.0479 (13.0)10 (14.5) 0.041Hepatitis (%)No8 (7.1)3 (4.1)0.531−0.1533 (4.3)3 (4.3)1.0000.000 Yes104 (92.9)70 (95.9) 0.15366 (95.7)66 (95.7) 0.000Child-pugh (%)A89 (79.5)61 (83.6)0.4870.11157 (82.6)57 (82.6)1.0000.000 B23 (20.5)12 (16.4) −0.11112 (17.4)12 (17.4) 0.000ECOG PS (%)080 (71.4)59 (80.8)0.1490.23955 (79.7)55 (79.7)1.0000.000 132 (28.6)14 (19.2) −0.23914 (20.3)14 (20.3) 0.000Tumor diameter, cmMean (SD)75.42 (37.28)71.93 (30.07)0.485−0.11670.22 (36.31)71.80 (30.25)0.7820.053AFP (%)<400 μg/L74 (66.1)52 (71.2)0.4620.11447 (68.1)48 (69.6)0.8540.032 ≥400 μg/L38 (33.9)21 (28.8) −0.11422 (31.9)21 (30.4) −0.032Total bilirubin, μmol/LMean (SD)16.66 (9.03)16.60 (8.49)0.968−0.00616.73 (8.90)16.60 (8.67)0.931−0.015Albumin, g/LMean (SD)37.59 (4.93)38.52 (5.02)0.2130.18738.40 (4.58)38.30 (5.05)0.898−0.021When not otherwise specified, data are given as numbers (and percentages).AFP: alpha-fetoprotein; DEB-TACE: drug-eluting bead chemoembolization; ECOG PS: eastern cooperative oncology group performance status; M-TACE: modified transarterial chemoembolization; SD: standard deviation; SMD: standard mean difference. Baseline characteristics of patients before and after PSM. When not otherwise specified, data are given as numbers (and percentages). AFP: alpha-fetoprotein; DEB-TACE: drug-eluting bead chemoembolization; ECOG PS: eastern cooperative oncology group performance status; M-TACE: modified transarterial chemoembolization; SD: standard deviation; SMD: standard mean difference. Initial tumor response At four to six weeks post-treatment, residual viable areas were frequently observed at the tumor margins after DEB-TACE (Figure 2). In our study, residual viable areas at the tumor margins were detected in 60.7% of patients (68/112) in the entire DEB-TACE group before PSM and in 56.5% of patients (39/69) after PSM. In contrast, the M-TACE group (Figure 3 and Figure S1) exhibited a significantly higher CR rate of 39.1% compared to 23.2% in the DEB-TACE group (p = 0.043). The ORR was similar between the groups (M-TACE: 100%, DEB-TACE: 98.6%) (Table 2). Additionally, patients in the M-TACE group required significantly fewer repeated treatments within six months compared to the DEB-TACE group (1.7 ± 0.9 vs. 2.1 ± 0.7, p = 0.033) (Table 2). Radiographical evidence of residual viable tumor areas at the margins after DEB-TACE treatment. (A1,B1,C1) Contrast-enhanced axial CT images in the arterial phase before DEB-TACE, showing an arterial enhancing mass located in the right hemiliver. (A2,B2,C2) Contrast-enhanced axial CT images in the arterial phase after DEB-TACE, demonstrating residual viable tumor areas at the tumor margins, indicated by red arrows (Patient A: a 47-year-old male; Patient B: a 72-year-old male; Patient C: a 66-year-old male). Radiographical depiction of a 68-year-old male with HCC undergoing M-TACE treatment. (A,B) Axial contrast-enhanced MRI images in the arterial (A) and portal (B) phases before M-TACE, revealing an enhancing lesion with a maximum diameter of 8.2 cm. (C) Hepatic arteriography showing a hypervascular tumor in the right hemiliver (arrow). (D) M-TACE procedure involving an injection of 4mL lipiodol-doxorubicin until the entire tumor outline becoming discernible (arrow), followed by embolization with CalliSpheres microspheres until near-stasis of the contrast agent flow. (E) Final angiography demonstrating complete tumor devascularization with no residual tumor staining in the right hemiliver. (F–H) Coronal (F) and axial (G,H) contrast-enhanced CT images in the arterial and portal phases, one month after initial M-TACE, showing a complete response in the treated tumor. Table 2.Comparison of initial tumor response and repeat treatment requirements within six months between the DEB-TACE and M-TACE. DEB-TACE(n = 69)M-TACE(n = 69)PValueRadiological tumor response CR, n (%)16 (23.2)27 (39.1)0.043aPR, n (%)52 (75.4)42 (60.9) SD, n (%)1 (1.4)0 (0) PD, n (%)0 (0)0 (0) ORR98.6%100%1.000bRepeated treatments within six monthsMean ± SD2.1 ± 0.71.7 ± 0.90.033aPearson chi-square test for CR vs. others; b Fisher’s exact test for CR + PR vs. others.DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate. Comparison of initial tumor response and repeat treatment requirements within six months between the DEB-TACE and M-TACE. aPearson chi-square test for CR vs. others; b Fisher’s exact test for CR + PR vs. others. DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate. LTP and survival Throughout the duration of follow-up, LTP occurred in 56 patients (81.2%) with M-TACE and 59 patients (85.5%) with DEB-TACE. Notably, the rates of LTP in the M-TACE group were significantly lower than those in the DEB-TACE group at 12 months (39.1% vs. 65.2%, p = 0.002). However, at 24 months and 36 months, the LTP rates exhibited no significant difference between M-TACE and DEB-TACE groups (72.5% vs. 82.6%, p = 0.153; 78.3% vs. 84.1%, p = 0.384). Patients who underwent M-TACE experienced a significantly greater median time to LTP when contrasted with those who used DEB-TACE (13.3vs. 8.2 months, p = 0.038) (Figure 4A). The median OS demonstrated no significant difference between M-TACE and DEB-TACE groups (32.3 vs. 32.2 months, p = 0.46) (Figure 4B). However, among patients achieving a CR after the initial TACE treatment, the median OS was notably longer after M-TACE compared to DEB-TACE (50.5 vs 33.4 months, p = 0.043) (Figure 4C). Kaplan–Meier curves depicting the time to local tumor progression (A) and overall survival in overall study population (B), as well as and in the subgroup of patients achieving CR after the initial TACE (C). In the multivariable Cox regression analysis, M-TACE demonstrated a significantly lower risk of LTP (hazard ratio [HR), 0.63; 95% confidence interval [CI], 0.43 to 0.91; p = 0.014]. Conversely, Child-Pugh Class B (HR, 2.11; 95% CI, 1.24 to 3.58; p = 0.006) and larger tumor diameter (HR, 1.02; 95% CI, 1.01 to 1.03; p = 0.004) were significantly associated with an increased risk of LTP (Table 3). For the entire group (n = 185), the tumor diameter’ is the only risk factor for OS (Table S2). Table 3.Univariable and multivariable Cox regression analysis of factors influencing LTP. UnivariableMultivariableCharacteristicHR95% CIP-valueHR95% CIP-valueGroup DEB-TACE–– –– M-TACE0.680.47, 0.980.0390.630.43, 0.910.014Sex Male–– Female1.340.82, 2.200.242 Age0.990.97, 1.010.207 Hepatitis No–– –– Yes0.960.39, 2.360.931 Child-Pugh score Class A–– –– Class B1.520.96, 2.400.0772.111.24, 3.580.006ECOG PS 0–– –– 11.681.07, 2.620.0230.650.29, 1.470.301Tumor diameter1.011.00, 1.020.0011.021.01, 1.030.004AFP <400 ng/mL–– –– ≥400 ng/mL1.370.92, 2.030.119 Total Bilirubin0.990.97, 1.010.565 Albumin1.030.99, 1.070.190 AFP: alpha-fetoprotein; DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization; HR: hazard ratio; CI: confidence interval. Univariable and multivariable Cox regression analysis of factors influencing LTP. AFP: alpha-fetoprotein; DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization; HR: hazard ratio; CI: confidence interval. Safety After treatment, 45 patients (65%) with M-TACE and 42 patients (61%) with DEB-TACE had post-embolization syndrome. Biloma occurred in three patients (4.3%) and one patient (1.4%) after their initial DEB-TACE and M-TACE treatment, respectively. Additionally, dilatation of the intrahepatic bile duct was detected in six cases (8.7%) with M-TACE and thirteen patients (19%) with DEB-TACE at one month after initial TACE. Importantly, no statistically significant difference was discovered in hepatic function between both groups one month following the intervention (Table 4). Table 4.Adverse events and liver function test results one month post-treatment.CharacteristicTreatment groupP-valueDEB-TACE(n = 69)M-TACE(n = 69)Post-embolization syndrome42 (61%)45 (65%)0.685Biloma3 (4.3%)1 (1.4%)0.518Bile duct dilatation13 (19%)6 (8.7%)0.200AST (U/L, mean ± SD) Baseline52 (26)56 (36)0.554 1-month follow-up57 (39)76 (66)0.144ALT (U/L, mean ± SD) Baseline43 (21)60 (65)0.157 1-month follow-up56 (44)48 (28)0.353Total bilirubin (μmol/L, mean ± SD) Baseline16.7 (8.9)16.6 (8.7)0.931 1-month follow-up17.2 (9.3)17.9 (9.4)0.409Albumin (g/L, mean ± SD) Baseline38.4 (4.6)38.3 (5.1)0.898 1-month follow-up38.3 (5.4)37.6 (4.0)0.524The data in parentheses are expressed as percentages, except where indicated.AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization. Adverse events and liver function test results one month post-treatment. The data in parentheses are expressed as percentages, except where indicated. AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; DEB-TACE: drug-eluting bead transarterial chemoembolization; M-TACE: modified transarterial chemoembolization. Discussion The present study demonstrates that M-TACE provides superior initial CR rates and longer time to LTP compared to DEB-TACE in patients with single HCC. Although median OS did not significantly differ between the groups, a stratified analysis revealed that patients achieving CR after initial TACE had notably longer OS with M-TACE. Additionally, patients undergoing M-TACE required significantly fewer repeated treatments within six months, indicating sustained efficacy and reducing the need for frequent interventions. To enhance the validity of our study, we have presented the results for the entire group (n = 185) in Table S2, identifying tumor diameter as the only significant risk factor. Utilizing PSM is crucial due to the retrospective nature of our study and the limited data collected, which could result in inter-group differences not reaching statistical significance and potentially leading to bias. By applying PSM, we aimed to address this issue and obtain more robust results. Following PSM, the SMD values for each influencing factor consistently decreased (all less than 0.1), indicating a successful reduction in these differences. This suggests that the use of PSM is meaningful, helps mitigate potential biases, and enhances the reliability of our findings. The ability of M-TACE to achieve higher initial CR rates suggests its potential for more effective tumor control. The higher CR rate may be explained by the combined therapeutic advantages of lipiodol-based emulsification and drug-eluting beads. Lipiodol can traverse sinusoids to reach the portal vein around the tumor, leading to a temporary blockage of sinusoids, portal vein, and arteriolar micro-connections [18,21,22]. This mechanism enhances the ­effectiveness of M-TACE for treating the residual tumor region. Additionally, the drug-eluting beads in M-TACE ­provide a controlled and sustained release of chemotherapy directly into the tumor, maximizing its efficacy while minimizing systemic exposure and side effects. Ikeda et al. conducted a randomized controlled study comparing cTACE and DEB-TACE for HCC <5cm, which showed that cTACE had a higher CR rate than DEB-TACE [14]. Our findings are consistent with this, as M-TACE, which combines the advantages of cTACE and DEB-TACE, also showed higher CR rates compared to DEB-TACE alone. Regarding the CR rates, our study found a CR rate of 39.1% for M-TACE, whereas Ikeda et al. reported an 84.2% CR rate for cTACE. This discrepancy can be attributed to the median tumor diameter in Ikeda et al.’s study being only 2 cm, compared to 6.5 cm in our study. Tumor size significantly influences CR rates, with larger tumors (>5 cm) often having lower CR rates than smaller HCCs [23]. It should be noted that significant differences in efficacy between cTACE and DEB-TACE were observed in Ikeda et al.’s study. However, as previously mentioned, some studies suggest that the disparity in efficacy between these two approaches may not be substantial [9,10]. Population heterogeneity and variations in statistical methodologies might contribute to these differences. The lower LTP rate and extended median time to LTP in the M-TACE group add another layer to the discussion. Previous analyses focused on tumor size have shown a notably extended time to target lesion progression with cTACE compared to DEB-TACE for tumors ≤ 3 cm. However, no such difference was observed for tumors > 3 cm [17]. Our study, which included patients with lesions > 3 cm, found that M-TACE exhibited a significantly longer time to LTP compared to DEB-TACE, suggesting that the modified approach provides more durable tumor control and reduces the likelihood of local tumor progression over time. The multivariable Cox regression analysis further supported M-TACE’s superiority in local tumor control. M-TACE demonstrated a manageable safety profile, with post-embolization syndrome being the most common AE. There was no statistically significant difference in the incidence of AEs between the M-TACE and DEB-TACE groups. Ikeda et al. reported that adverse events were significantly higher in the cTACE group compared to the DEB-TACE group [14]. Although our study did not directly compare M-TACE with cTACE, the adverse event profile of M-TACE was similar to that of DEB-TACE. This suggests that M-TACE may have a lower incidence of adverse events compared to cTACE, based on the lower adverse event rates reported for DEB-TACE in Ikeda et al.’s study. This implies that M-TACE not only leverages the higher CR rates associated with cTACE but also mitigates its higher adverse event rates, thus providing a more favorable safety profile. We recognize the absence of a cTACE comparison group in our study makes it difficult to conclusively explain the increased initial CR observed in the M-TACE group and the similar safety profiles between M-TACE and DEB-TACE. Although the reduced amount of lipiodol used in M-TACE compared to cTACE might contribute to its safety, this remains speculative without direct comparison data. Future studies should include a cTACE group to better elucidate these findings and provide a more comprehensive comparison. Our study has several limitations. First, as mentioned, the absence of a cTACE comparison group is a significant limitation. Second, the total amount of chemotherapy drugs used in the M-TACE group is slightly higher than that in the DEB-TACE group, which may have a potential impact on enhancing efficacy. Third, in the M-TACE group, some patients underwent a one-month postoperative assessment using CT, where artifacts from iodized oil deposits might interfere with the detection of small active lesions, potentially leading to an overestimation of M-TACE efficacy. Fourth, while a stratified analysis revealed a notably longer OS in individuals achieving a CR after the initial M-TACE, the overall study population did not show a significant difference in OS between the two groups. Factors such as variations in post-progression treatments, including systemic therapy, could impact overall survival, masking potential significant differences. Additionally, the relatively limited number of cases in the study may impact the statistical significance of results. Increasing the sample size could potentially uncover more robust insights, particularly regarding overall survival. Conclusions Our study indicates that M-TACE achieves higher initial CR rates and longer time to LTP compared to DEB-TACE in patients with single HCC. These findings suggest that M-TACE may offer enhanced tumor control in the early stages of treatment. However, no significant difference in overall survival (OS) was observed between the two groups. Further multicenter randomized controlled trials with larger sample sizes are necessary to validate these findings. Supplementary Material Supplemental Material Acknowledgments We would like to thank Wenjun He (Department of Medical Statistic and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China) for statistical assistance in the manuscript. Funding Statement This study was supported by GuangDong Basic and Applied Basic Research Foundation (2021A1515111024, 2023A1515012344); Guangzhou Basic and Applied Basic Research Foundation (202201011062, 202201010973). Informed consent statement Patient consent was waived due to the retrospective nature. Authors’ contributions B.C. and C.Z. carried out the studies and wrote the manuscript. M.H. and M.B. designed the study and collected data. C.L. and L.M. participated in acquisition and analysis of data. All authors read and approved the final manuscript. Institutional review board statement This study was approved by the Ethics Committee of Sun Yat-sen University’s Third Affiliated Hospital (No. II2023-020-01). Disclosure statement The authors declare that they have no competing interests. Data availability statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. References Associated Data Supplementary Materials Supplemental Material Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.